Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 12

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 12
---
ulated vote at the time of the Special Meeting, there are not sufficient votes to approve the Business Combination Proposal (Proposal No. 7).

**Each of these proposals is more fully described in this proxy statement/prospectus.

The Iris Class A Common Stock, Iris Units and Public Warrants are currently traded on the OTC Pink Marketplace under the symbols “IRAA,” “IRAAU” and “IRAAW,” respectively. ParentCo will apply to list, to be effective at the time of the Business Combination, its common stock and warrants on the Nasdaq Global Market under the market value standard, under the symbols “LIMN” and “LIMNW,” respectively. At the Effective Time, we expect ParentCo will satisfy all of the initial listing requirements under the market value standard; however, we currently do not meet the Round Lot Requirement. We have engaged a securities market advisory firm to assist with obtaining the requisite number of round lot stockholders to satisfy the Round Lot Requirement before the Business Combination is consummated. We expect the Iris Class A Common Stock, Iris Units and Public Warrants will then cease trading on the OTC Pink Marketplace.

After the completion of the Business Combination, Liminatus Members will beneficially own approximately 65.4% of the combined voting power of the ParentCo Common Stock, assuming no redemptions (or 65.8% assuming maximum redemptions), and Liminatus’s current principal member, Chris Kim, will be deemed to beneficially own approximately 23.0% of the outstanding voting power of ParentCo Common Stock, assuming no redemptions (or 23.2% assuming maximum redemptions).

Pursuant to our amended and restated certificate of incorporation (as amended, the “Iris Certificate of Incorporation”), we are providing holders of the shares of Iris Class A Common Stock (such holders, the “public stockholders”) with the opportunity, upon the closing of the Transactions and subject to the limitations described in this proxy statement/prospectus, to redeem their shares of Iris Class A Common Stock for cash equal to their pro rata share of the aggregate amount on deposit (as of two business days prior to the consummation of the Transactions) in our Trust Account (as defined herein). For illustrative purposes, based on funds in our Trust Account of approximately $2,001,033 (as adjusted for redemptions paid out of the Trust Account in January 2025) as of January 2, 2025, stock